ZK 137316

Drug Profile

ZK 137316

Latest Information Update: 28 Aug 2002

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer Schering Pharma; Nonindustrial source
  • Class Antiprogestogens; Contraceptives; Hormones
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pregnancy

Most Recent Events

  • 22 Feb 1999 New profile
  • 22 Oct 1997 Preclinical development for Pregnancy (Prevention) in Germany (Unknown route)
  • 22 Oct 1997 Preclinical development for Pregnancy (Prevention) in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top